The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Leukocyte immunoglobulin-like receptor (LILRB2)-targeted JTX-8064 plus the anti-PD1 inhibitor JTX-4014 (pimivalimab) in immune-checkpoint inhibitor (ICl)­ pretreated patients (pts) with advanced or metastatic renal cell cancer (mRCC): Results from the multi-stage phase 1-2 INNATE trial.
 
Primo N. Lara
Research Funding - AstraZeneca (Inst); Taiho Pharmaceutical (Inst)
 
Stew Kroll
Employment - Jounce Therapeutics
 
Jonathan Alexander Chatzkel
No Relationships to Disclose
 
Deanna Gek Koon Teoh
Research Funding - Jounce Therapeutics (Inst); Moderna Therapeutics (Inst); Tesaro/GSK (Inst)
 
Vincent T Ma
Honoraria - Conquer Cancer, the ASCO Foundation; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Bristol Myers Squibb; General Dynamics Information Technology; Immunocore; Incyte; Partner Therapeutics; Regeneron; Replimune; Targeted Oncology; Teiko.bio
Research Funding - AIQ Solutions (Inst); C4 Therapeutics (Inst); Fujifilm (Inst); Immunocore (Inst); Innate Pharma (Inst); Jounce Therapeutics (Inst); Natera (Inst); Seagen (Inst); Top Alliance BioScience (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Incyte
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis; Merck Sharp & Dohme; Pfizer
Speakers' Bureau - Astellas Pharma; AVEO; Exelixis; Janssen
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AVEO; Exelixis; Janssen
 
Clara Hwang
Stock and Other Ownership Interests - Johnson & Johnson/Janssen (I)
Consulting or Advisory Role - EMD Serono; Genzyme; TEMPUS
Speakers' Bureau - OncLive/MJH Life Sciences
Research Funding - AstraZeneca (Inst); Bausch Health (Inst); Bayer (Inst); Genentech (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Merck
 
Randy F. Sweis
Stock and Other Ownership Interests - Abbvie (I)
Honoraria - AVEO
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Gilead Sciences; Loxo/Lilly; Pfizer; Seattle Genetics/Astellas
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Ascendis Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Eisai (Inst); EpiVax Oncology (Inst); Genentech (Inst); Immunocore (Inst); Jounce Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pionyr (Inst); Pyxis (Inst); QED Therapeutics (Inst); Scholar Rock (Inst)
Patents, Royalties, Other Intellectual Property - Neoantigens in Cancer, PCT/US2020/031357
 
Kiran Yalamanchili
No Relationships to Disclose
 
Julio Antonio Peguero
Employment - Oncology Consultants
Leadership - Oncology Consultants
Stock and Other Ownership Interests - Consultores en Oncologia; Oncology Consultants; zogen
Consulting or Advisory Role - Exigent Research Network
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BerGenBio (Inst); Dizal Pharma (Inst); eFFECTOR Therapeutics (Inst); Epizyme (Inst); Genentech/Roche (Inst); ImmunityBio (Inst); Immutep (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Kechow Pharma (Inst); Lilly (Inst); Macrogenics (Inst); Mirati Therapeutics (Inst); Natera (Inst); Novartis (Inst); OncoC4 (Inst); QSAM (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Systimmune (Inst)
 
Tianhong Li
Consulting or Advisory Role - Bristol Myers Squibb; Janssen
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma USA (Inst); Duality Biologics (Inst); Genentech (Inst); Jounce Therapeutics (Inst); LabyRx Immuno-Oncology (Inst); Lung Cancer Mutation Consortium (Inst); Merck (Inst); Novartis (Inst); Nvigen (Inst); OncoImmune/OncoC4 (Inst); RasCal (Inst); Tempus (Inst); Xilio Therapeutics (Inst)
 
Mamta Parikh
Consulting or Advisory Role - Bristol Myers Squibb; Natera; Pfizer-Myovant; Sanofi/Aventis
Research Funding - Gilead Sciences; Karyopharm Therapeutics